NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancer.
Syrine Sghaier, Pauline Corbaux, Isabelle Ray-Coquard...
https://pubmed.ncbi.nlm.nih.gov/37650734/Actively Recruiting
Led by ARCAGY/ GINECO GROUP · Updated on 2026-04-13
390
Participants Needed
88
Research Sites
260 weeks
Total Duration
Researchers are evaluating the effectiveness of maintenance treatments using niraparib alone versus niraparib combined with bevacizumab in women newly diagnosed with advanced stage IIIA, IIIB, or IIIC high-grade epithelial ovarian cancer who have no visible disease remaining after initial surgery and chemotherapy. This phase II, randomized, open-label multicenter trial aims to compare these approaches following frontline surgery and adjuvant platinum-based chemotherapy with or without bevacizumab. Patients are stratified by BRCA status, cancer stage, and prior hyperthermic intraperitoneal chemotherapy. The study treatments include two groups one receiving carboplatin and paclitaxel chemotherapy over five cycles followed by daily oral niraparib for two years, and the other receiving the same chemotherapy plus bevacizumab for five cycles, then maintenance with both bevacizumab every three weeks for 15 months and daily niraparib for two years. Bevacizumab is administered intravenously starting with the second chemotherapy cycle. The trial investigates the impact of these regimens on progression-free survival and other long-term outcomes. Participants will undergo regular assessments including imaging scans between surgery and chemotherapy to confirm no disease, laboratory tests to monitor organ and bone marrow function, and physical exams during treatment. Researchers will track progression-free survival up to 24 months and other outcomes such as time to subsequent treatments, long-term overall survival, and treatment safety over up to five years. The study involves a total participation period that includes treatment and follow-up evaluations.
CONDITIONS
Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
S
Sidonie Adam
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
ARCAGY/ GINECO GROUP
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 2 years (including chemotherapy and maintenance treatment)
Participants receive chemotherapy with carboplatin and paclitaxel for 5 cycles every 3 weeks. Depending on the treatment arm, bevacizumab is added starting from the second chemotherapy cycle for 5 cycles and may continue during the maintenance phase. After chemotherapy, participants take niraparib orally once daily continuously for up to 2 years as maintenance treatment. Bevacizumab, if assigned, continues for a total of 15 months.
5 chemotherapy cycles with weekly visits every 3 weeks, followed by regular maintenance visits during niraparib and bevacizumab treatment
Duration - Up to 5 years
Participants are monitored for progression-free survival, overall survival, and long-term safety outcomes for up to 5 years after treatment.
Periodic visits for assessments during follow-up
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Syrine Sghaier, Pauline Corbaux, Isabelle Ray-Coquard...
https://pubmed.ncbi.nlm.nih.gov/37650734/ARCAGY/ GINECO GROUP
Lead Sponsor